These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9421870)

  • 61. Hypothesis testing for two-stage designs with over or under enrollment.
    Zeng D; Gao F; Hu K; Jia C; Ibrahim JG
    Stat Med; 2015 Jul; 34(16):2417-26. PubMed ID: 25809924
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sample size determination and treatment screening in two-stage phase II clinical trials via ROC curve.
    Huang WS; Chang YI
    Pharm Stat; 2018 Sep; 17(5):504-514. PubMed ID: 29722125
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phase II trials powered to detect tumor subtypes.
    Roberts JD; Ramakrishnan V
    Clin Cancer Res; 2011 Sep; 17(17):5538-45. PubMed ID: 21737510
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A confidence function-based posterior probability design for phase II cancer trials.
    Shan M
    Pharm Stat; 2021 May; 20(3):485-498. PubMed ID: 33336856
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimal multistage designs for randomised clinical trials with continuous outcomes.
    Wason JM; Mander AP; Thompson SG
    Stat Med; 2012 Feb; 31(4):301-12. PubMed ID: 22139822
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Optimal two-stage log-rank test for randomized phase II clinical trials.
    Kwak M; Jung SH
    J Biopharm Stat; 2017; 27(4):639-658. PubMed ID: 27050043
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Optimal two-stage randomized phase II clinical trials.
    Logan BR
    Clin Trials; 2005; 2(1):5-12. PubMed ID: 16279574
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bayesian two-stage designs for phase II clinical trials.
    Tan SB; Machin D
    Stat Med; 2002 Jul; 21(14):1991-2012. PubMed ID: 12111883
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Optimal two-stage designs for phase II clinical trials.
    Simon R
    Control Clin Trials; 1989 Mar; 10(1):1-10. PubMed ID: 2702835
    [TBL] [Abstract][Full Text] [Related]  

  • 70. When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay.
    Mukherjee A; Wason JMS; Grayling MJ
    Eur J Cancer; 2022 May; 166():270-278. PubMed ID: 35344852
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alternative designs of phase II trials considering response and toxicity.
    Jin H
    Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Optimal continuous-monitoring design of single-arm phase II trial based on the simulated annealing method.
    Chen N; Lee JJ
    Contemp Clin Trials; 2013 May; 35(1):170-8. PubMed ID: 23545075
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An MSE-reduced estimator for the response proportion in a two-stage clinical trial.
    Li Q
    Pharm Stat; 2011; 10(3):277-9. PubMed ID: 20140880
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
    Zhang Y; Mietlowski W; Chen B; Wang Y
    J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A design of phase II cancer trials using total and complete response endpoints.
    Lu Y; Jin H; Lamborn KR
    Stat Med; 2005 Oct; 24(20):3155-70. PubMed ID: 16189806
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Curtailed two-stage designs with two dependent binary endpoints.
    Chen CM; Chi Y
    Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Optimal sequential enrichment designs for phase II clinical trials.
    Zang Y; Yuan Y
    Stat Med; 2017 Jan; 36(1):54-66. PubMed ID: 27640874
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Interval estimation of binomial proportion in clinical trials with a two-stage design.
    Tsai WY; Chi Y; Chen CM
    Stat Med; 2008 Jan; 27(1):15-35. PubMed ID: 17566141
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Exact two-stage designs for phase II activity trials with rank-based endpoints.
    Wilding GE; Shan G; Hutson AD
    Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.
    Mauer M; Collette L; Bogaerts J;
    Eur J Cancer; 2012 Jun; 48(9):1386-91. PubMed ID: 22281098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.